Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?
An erratum to this article was published (J Clin Endocrinol Metab, 16 Sep 2024 ↗)
Authors' conclusion
In patients with uncontrolled CTX levels after Dmab withdrawal, 2 ZOL infusions 6 months apart do not prevent BMD loss and FX.
Study context
- Population
- Patients discontinuing denosumab managed according to European Calcified Tissue Society (ECTS) recommendations; Zoledronate (ZOL) 1 month after denosumab (Dmab) withdrawal
- Participants
- 52 patients
- Exposure
- Repeated ZOL infusion vs single ZOL infusion after Dmab discontinuation
- Outcome
- BMD changes and fracture rate
- Follow-up
- On average 17 months from Dmab withdrawal
Main finding
As reported in the abstract
Spine BMD change
2 ZOL infusions
−5.5
± 5.6 · %
CTX <280 ng/L
−0.1
± 5.5 · %
P = 0.008
- Patients who repeated ZOL infusion
- 75%
- Fractured patients
- 9.6%
Observational data: associations, not effects.
Further findings
Predictors of bone mineral density (BMD) worsening after Dmab withdrawal
- CTX t1: OR (IQR 1.3-6.6), P = .009
- 2.9
- Spine BMD gain during Dmab therapy corrected for number of Dmab injections: OR (IQR 1.2-7.2), P = .014
- 3.0
- Sensitivity of CTX at t1 > 212 ng/L for predicting BMD loss
- 100%
Original publication
Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion? J Clin Endocrinol Metab. Published 13 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →